NgM, FlemingT, RobinsonM, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384, 766–781.
HossainP, KawarB, El NahasM. Obesity and diabetes in the developing world – a growing challenge. N Engl J Med. 2007; 356, 213–215.
CordainL, EatonSB, SebastianA, et al. Origins and evolution of the western diet: health implications for the 21st century. Am J Clin Nutr. 2005; 81, 341–354.
MokdadAH, FordES, BowmanBA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289, 76–79.
WilsonRM, MessaoudiI. The impact of maternal obesity during pregnancy on offspring immunity. Mol Cell Endocrinol. 2015; 418, 134–142.
SebireNJ, JollyM, HarrisJ, et al. Maternal obesity and pregnancy outcome: a study of 287 213 pregnancies in London. Int J Obes (Lond). 2001; 25, 1175–1182.
CatalanoPM, EhrenbergHM. The short- and long-term implications of maternal obesity on the mother and her offspring. BJOG. 2006; 113, 1126–1133.
WhitakerRC. Predicting preschooler obesity at birth: the role of maternal obesity in early pregnancy. Pediatrics. 2004; 114, e29–e36.
BoneyCM, VermaA, TuckerR, et al. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005; 115, e290–e296.
YuZ, HanS, ZhuJ, et al. Pre-pregnancy body mass index in relation to infant birth weight and offspring overweight/obesity: a systematic review and meta-analysis. PLoS One. 2013; 8, e61627.
VickersM. Developmental programming and transgenerational transmission of obesity. Ann Nutr Metab. 2014; 64, 26–34.
O’ReillyJR, ReynoldsRM. The risk of maternal obesity to the long‐term health of the offspring. Clin Endocrinol (Oxf). 2013; 78, 9–16.
KingJC. Maternal obesity, metabolism, and pregnancy outcomes. Annu Rev Nutr. 2006; 26, 271–291.
RamsayJE, FerrellWR, CrawfordL, et al. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocr Metab. 2002; 87, 4231–4237.
LumengCN, SaltielAR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011; 121, 2111–2117.
KershawEE, FlierJS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89, 2548–2556.
LumengCN, BodzinJL, SaltielAR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007; 117, 175–184.
DroletR, BélangerC, FortierM, et al. Fat depot‐specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity. 2009; 17, 424–430.
KimJK, GavrilovaO, ChenY, et al. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem. 2000; 275, 8456–8460.
YeJ, GaoZ, YinJ, et al. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab. 2007; 293, E1118–E1128.
WeisbergSP, McCannD, DesaiM, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112, 1796–1808.
FainJN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006; 74, 443–477.
SilhaJV, KrsekM, SkrhaJV, et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003; 149, 331–335.
CnopM, HavelP, UtzschneiderK, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003; 46, 459–469.
WildmanRP, MuntnerP, ReynoldsK, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008; 168, 1617–1624.
Mongraw-ChaffinM, FosterMC, KalyaniRR, et al. Obesity severity and duration are associated with incident metabolic syndrome: evidence against metabolically healthy obesity from the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. 2016; 101, 4117–4124.
HinnouhoGM, CzernichowS, DugravotA, et al. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter?
Diabetes Care. 2013; 36, 2294–2300.
HotamisligilGS, ShargillNS, SpiegelmanBM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259, 87–91.
HotamisligilGS, ArnerP, CaroJF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995; 95, 2409–2415.
ChenX, XunK, ChenL, et al. TNF‐α, a potent lipid metabolism regulator. Cell Biochem Funct. 2009; 27, 407–416.
UysalKT, WiesbrockSM, MarinoMW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 1997; 389, 610–614.
LagathuC, Yvan-CharvetL, BastardJ, et al. Long-term treatment with interleukin-1β induces insulin resistance in murine and human adipocytes. Diabetologia. 2006; 49, 2162–2173.
McGillicuddyFC, HarfordKA, ReynoldsCM, et al. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes. 2011; 60, 1688–1698.
KimJ, BachmannRA, ChenJ. Interleukin‐6 and insulin resistance. Vitam Horm. 2009; 80, 613–633.
Mohamed-AliV, GoodrickS, RaweshA, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo 1. J Clin Endocrinol Metab. 1997; 82, 4196–4200.
RotterV, NagaevI, SmithU. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003; 278, 45777–45784.
SennJJ, KloverPJ, NowakIA, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002; 51, 3391–3399.
PedersenBK, SteensbergA, SchjerlingP. Muscle‐derived interleukin‐6: possible biological effects. J Physiol (Lond). 2001; 536, 329–337.
HuFB, MeigsJB, LiTY, et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004; 53, 693–700.
KoppHP, KoppCW, FestaA, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003; 23, 1042–1047.
MatthewsV, AllenT, RisisS, et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia. 2010; 53, 2431–2441.
van ExelE, GusseklooJ, de CraenAJ, et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes : the Leiden 85-Plus Study. Diabetes. 2002; 51, 1088–1092.
FiorentinoDF, ZlotnikA, MosmannTR, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991; 147, 3815–3822.
BeloL, Santos-SilvaA, RochaS, et al. Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005; 123, 46–51.
ZhangL, SugiyamaT, MurabayashiN, et al. The inflammatory changes of adipose tissue in late pregnant mice. J Mol Endocrinol. 2011; 47, 157–165.
MadanJC, DavisJM, CraigWY, et al. Maternal obesity and markers of inflammation in pregnancy. Cytokine. 2009; 47, 61–64.
RetnakaranR, HanleyAJ, RaifN, et al. C-reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metab. 2003; 88, 3507–3512.
BasuS, HaghiacM, SuraceP, et al. Pregravid obesity associates with increased maternal endotoxemia and metabolic inflammation. Obesity. 2011; 19, 476–482.
KalagiriRR, CarderT, ChoudhuryS, et al. Inflammation in complicated pregnancy and its outcome. Am J Perinatol. 2016; 14, 1337–1356.
ArenzS, RückerlR, KoletzkoB, et al. Breast-feeding and childhood obesity – a systematic review. Int J Obes. 2004; 28, 1247–1256.
PanagosP, VishwanathanR, Penfield-CyrA, et al. Breastmilk from obese mothers has pro-inflammatory properties and decreased neuroprotective factors. J Perinatol. 2016; 36, 284–290.
MorignyP, HoussierM, MouiselE, et al. Adipocyte lipolysis and insulin resistance. Biochimie. 2016; 125, 259–266.
ZambranoE, NathanielszPW. Mechanisms by which maternal obesity programs offspring for obesity: evidence from animal studies. Nutr Rev. 2013; 71(Suppl. 1), S42–S54.
TschopM, WeyerC, TataranniPA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50, 707–709.
ColldenG, BallandE, ParkashJ, et al. Neonatal overnutrition causes early alterations in the central response to peripheral ghrelin. Mol Metab. 2015; 4, 15–24.
HuhSY, Rifas-ShimanSL, TaverasEM, et al. Timing of solid food introduction and risk of obesity in preschool-aged children. Pediatrics. 2011; 127, e544–e551.
RadaelliT, Uvena-CelebrezzeJ, MiniumJ, et al. Maternal interleukin-6: marker of fetal growth and adiposity. J Soc Gynecol Investig. 2006; 13, 53–57.
McCloskeyK, PonsonbyA, CollierF, et al.The association between higher maternal pre‐pregnancy body mass index and increased birth weight, adiposity and inflammation in the newborn. Pediatr Obes. 2016. https://doi.org/10.1111/ijpo.12187.
GaillardR, Rifas‐ShimanSL, PerngW, et al. Maternal inflammation during pregnancy and childhood adiposity. Obesity. 2016; 24, 1320–1327.
FarahN, HoganAE, O’ConnorN, et al. Correlation between maternal inflammatory markers and fetomaternal adiposity. Cytokine. 2012; 60, 96–99.
Toledo BaldiE, Dias BóbboV, Melo LimaM, et al. Tumor necrosis factor‐alpha levels in blood cord is directly correlated with the body weight of mothers. Obes Sci Pract. 2016; 2, 210–214.
DanielsenI, GranströmC, RytterD, et al. Subclinical inflammation during third trimester of pregnancy was not associated with markers of the metabolic syndrome in young adult offspring. Obesity. 2014; 22, 1351–1358.
OnoreCE, SchwartzerJJ, CareagaM, et al. Maternal immune activation leads to activated inflammatory macrophages in offspring. Brain Behav Immun. 2014; 38, 220–226.
KirstenTB, LippiLL, BevilacquaE, et al. LPS exposure increases maternal corticosterone levels, causes placental injury and increases IL-1Beta levels in adult rat offspring: relevance to autism. PLoS One. 2013; 8, e82244.
NilssonC, LarssonB, JennischeE, et al. Maternal endotoxemia results in obesity and insulin resistance in adult male offspring 1. Endocrinology. 2001; 142, 2622–2630.
MurabayashiN, SugiyamaT, ZhangL, et al. Maternal high-fat diets cause insulin resistance through inflammatory changes in fetal adipose tissue. Eur J Obstet Gyn R B. 2013; 169, 39–44.
AlfaradhiMZ, KusinskiLC, Fernandez-TwinnDS, et al. Maternal obesity in pregnancy developmentally programs adipose tissue inflammation in young, lean male mice offspring. Endocrinology. 2016; 157, 4246–4256.
ChallierJC, BasuS, BinteinT, et al. Obesity in pregnancy stimulates macrophage accumulation and inflammation in the placenta. Placenta. 2008; 29, 274–281.
ZhuMJ, DuM, NathanielszPW, et al. Maternal obesity up-regulates inflammatory signaling pathways and enhances cytokine expression in the mid-gestation sheep placenta. Placenta. 2010; 31, 387–391.
HalaasJL, GajiwalaKS, MaffeiM, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995; 269, 543–546.
LoffredaS, YangSQ, LinHZ, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998; 12, 57–65.
LappasM, PermezelM, RiceGE. Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-κB, peroxisomal proliferator-activated receptor-γ and extracellularly regulated kinase 1/2. Endocrinology. 2005; 146, 3334–3342.
SchwartzMW, PeskindE, RaskindM, et al. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med. 1996; 2, 589–593.
ShankarK, HarrellA, LiuXL, et al. Maternal obesity at conception programs obesity in the offspring. Am J Physiol-Reg I. 2008; 294, R528–R538.
ObenJA, MouralidaraneA, SamuelssonAM, et al. Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice. J Hepatol. 2010; 52, 913–920.
SáinzN, González-NavarroCJ, MartínezJA, et al. Leptin signaling as a therapeutic target of obesity. Expert Opin Ther Targets. 2015; 19, 893–909.
LihnAS, BruunJM, HeG, et al. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004; 219, 9–15.
ParkK, ParkKS, KimM, et al. Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract. 2004; 63, 135–142.
YamauchiT, KamonJ, MinokoshiYa, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8, 1288–1295.
OhashiK, ParkerJL, OuchiN, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem. 2010; 285, 6153–6160.
JonesHN, WoollettLA, BarbourN, et al. High-fat diet before and during pregnancy causes marked up-regulation of placental nutrient transport and fetal overgrowth in C57/BL6 mice. FASEB J. 2009; 23, 271–278.
AyeIL, RosarioFJ, PowellTL, et al. Adiponectin supplementation in pregnant mice prevents the adverse effects of maternal obesity on placental function and fetal growth. Proc Natl Acad Sci U S A. 2015; 112, 12858–12863.
SabenJ, LindseyF, ZhongY, et al. Maternal obesity is associated with a lipotoxic placental environment. Placenta. 2014; 35, 171–177.
DoschNC, GuslitsEF, WeberMB, et al. Maternal obesity affects inflammatory and iron indices in umbilical cord blood. J Pediatr. 2016; 172, 20–28.
KroenerL, WangET, PisarskaMD. Predisposing factors to abnormal first trimester placentation and the impact on fetal outcomes. Semin Reprod Med. 2016; 34, 27–35.
HayesEK, TessierDR, PercivalME, et al. Trophoblast invasion and blood vessel remodeling are altered in a rat model of lifelong maternal obesity. Reprod Sci. 2014; 21, 648–657.
LagerS, JanssonN, OlssonA, et al. Effect of IL-6 and TNF-α on fatty acid uptake in cultured human primary trophoblast cells. Placenta. 2011; 32, 121–127.
HuangL, LiuJ, FengL, et al. Maternal prepregnancy obesity is associated with higher risk of placental pathological lesions. Placenta. 2014; 35, 563–569.
MarkP, SisalaC, ConnorK, et al. A maternal high-fat diet in rat pregnancy reduces growth of the fetus and the placental junctional zone, but not placental labyrinth zone growth. J DOHaD. 2011; 2, 63–70.
MarkP, LewisJ, JonesM, et al. The inflammatory state of the rat placenta increases in late gestation and is further enhanced by glucocorticoids in the labyrinth zone. Placenta. 2013; 34, 559–566.
FarleyD, ChoiJ, DudleyD, et al. Placental amino acid transport and placental leptin resistance in pregnancies complicated by maternal obesity. Placenta. 2010; 31, 718–724.
Leon-GarciaSM, RoederHA, NelsonKK, et al. Maternal obesity and sex-specific differences in placental pathology. Placenta. 2016; 38, 33–40.
DitchfieldA, DesforgesM, MillsT, et al. Maternal obesity is associated with a reduction in placental taurine transporter activity. Int J Obes. 2014; 4, 557–564.
DubeE, GravelA, MartinC, et al. Modulation of fatty acid transport and metabolism by maternal obesity in the human full-term placenta. Biol Reprod. 2012; 87, 1–11.
Langley-EvansSC. Developmental programming of health and disease. Proc Nutr Soc. 2006; 65, 97–105.
HansonMA, GluckmanPD. Early developmental conditioning of later health and disease: physiology or pathophysiology?
Physiol Rev. 2014; 94, 1027–1076.
PetersenAM, PedersenBK. The anti-inflammatory effect of exercise.
J Appl Physiol (1985). 2005; 98, 1154–1162.
FordES. Does exercise reduce inflammation? Physical activity and C-reactive protein among US adults. Epidemiology. 2002; 13, 561–568.
VegaCC, Reyes-CastroLA, BautistaCJ, et al. Exercise in obese female rats has beneficial effects on maternal and male and female offspring metabolism. Int J Obes. 2013; 4, 712–719.
Bae-GartzI, JanoschekR, KloppeCS, et al. Running exercise in obese pregnancies prevents IL-6 trans-signaling in male offspring. Med Sci Sports Exerc. 2016; 48, 829–838.
TiniusRA, CahillAG, StrandEA, et al. Maternal inflammation during late pregnancy is lower in physically active compared with inactive obese women. Appl Physiol Nutr Metab. 2015; 41, 191–198.
ChenH, SimarD, PeggK, et al. Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents. Diabetologia. 2014; 57, 614–622.
HeliövaaraM, HerzM, TeppoA, et al. Pioglitazone has anti-inflammatory effects in patients with type 2 diabetes. J Endocrinol Invest. 2007; 30, 292–297.
KalanderianA, AbateN, PatrikeevI, et al. Pioglitazone therapy in mouse offspring exposed to maternal obesity. Am J Obstet Gynecol. 2013; 208, 308 e1–7.
DesaiN, RomanA, RochelsonB, et al. Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome. Am J Obstet Gynecol. 2013; 209, 136.e1–9.
HarrisK, DesaiN, GuptaM, et al. The effects of prenatal metformin on obesogenic diet-induced alterations in maternal and fetal fatty acid metabolism. Nutr Metab (Lond). 2016; 13, 55.
SalomäkiH, HeinäniemiM, VähätaloLH, et al. Prenatal metformin exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring. PLoS One. 2014; 9, e115778.
ChiswickCA, ReynoldsRM, DenisonFC, et al. Efficacy of metformin in pregnant obese women: a randomised controlled trial. BMJ Open. 2015; 5, e006854.
ChiswickC, ReynoldsRM, DenisonF, et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015; 3, 778–786.
NovakTE, BabcockTA, JhoDH, et al. NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol. 2003; 284, L84–L89.
NeschenS, MorinoK, RossbacherJC, et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes. 2006; 55, 924–928.
HaghiacM, YangX, PresleyL, et al. Dietary omega-3 fatty acid supplementation reduces inflammation in obese pregnant women: a randomized double-blind controlled clinical trial. PLoS One. 2015; 10, e0137309.
MelodyS, VincentR, MoriT, et al. Effects of omega-3 and omega-6 fatty acids on human placental cytokine production. Placenta. 2015; 36, 34–40.
MoonR, HarveyN, RobinsonS, et al. Maternal plasma polyunsaturated fatty acid status in late pregnancy is associated with offspring body composition in childhood. J Clin Endocrinol Metab. 2012; 98, 299–307.
RytterD, BechBH, HalldorssonT, et al. No association between the intake of marine n-3 PUFA during the second trimester of pregnancy and factors associated with cardiometabolic risk in the 20-year-old offspring. Br J Nutr. 2013; 110, 2037–2046.
BreiC, StecherL, MuchD, et al. Reduction of the n-6:n-3 long-chain PUFA ratio during pregnancy and lactation on offspring body composition: follow-up results from a randomized controlled trial up to 5 y of age. Am J Clin Nutr. 2016; 103, 1472–1481.
StratakisN, GielenM, ChatziL, et al. Effect of maternal n-3 long-chain polyunsaturated fatty acid supplementation during pregnancy and/or lactation on adiposity in childhood: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2014; 68, 1277–1287.
SimopoulosAP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002; 56, 365–379.
SimopoulosAP. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients. 2016; 8, 128.
HeerwagenMJ, StewartMS, de la HoussayeBA, et al. Transgenic increase in n-3/n-6 fatty acid ratio reduces maternal obesity-associated inflammation and limits adverse developmental programming in mice. PLoS One. 2013; 8, e67791.
HussainA, NookaewI, KhoomrungS, et al. A maternal diet of fatty fish reduces body fat of offspring compared with a maternal diet of beef and a post‐weaning diet of fish improves insulin sensitivity and lipid profile in adult C57BL/6 male mice. Acta Physiol (Oxf). 2013; 209, 220–234.
BagleyHN, WangY, CampbellMS, et al. Maternal docosahexaenoic acid increases adiponectin and normalizes IUGR-induced changes in rat adipose deposition. J Obes. 2013; 2013, 312153.
MuhlhauslerBS, MiljkovicD, FongL, et al. Maternal omega-3 supplementation increases fat mass in male and female rat offspring. Front Genet. 2011; 2, 48.
ZulkafliIS, WaddellBJ, MarkPJ. Postnatal dietary omega-3 fatty acid supplementation rescues glucocorticoid-programmed adiposity, hypertension, and hyperlipidemia in male rat offspring raised on a high-fat diet. Endocrinology. 2013; 154, 3110–3117.
MarkPJ, WyrwollCS, ZulkafliIS, et al. Rescue of glucocorticoid-programmed adipocyte inflammation by omega-3 fatty acid supplementation in the rat. Reprod Biol Endocrinol. 2014; 12, 1.
ChiccoA, CreusA, IllescaP, et al. Effects of post-suckling n-3 polyunsaturated fatty acids: prevention of dyslipidemia and liver steatosis induced in rats by a sucrose-rich diet during pre-and post-natal life. Food Funct. 2016; 7, 445–454.
BalogunKA, CheemaSK. Dietary omega-3 fatty acids prevented adipocyte hypertrophy by downregulating DGAT-2 and FABP-4 in a sex-dependent fashion. Lipids. 2016; 51, 25–38.
MuhlhauslerB, GibsonR, MakridesM. The effect of maternal omega-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation during pregnancy and/or lactation on body fat mass in the offspring: a systematic review of animal studies. Prostaglandins Leukot Essent Fatty Acids. 2011; 85, 83–88.
MennittiLV, OliveiraJL, MoraisCA, et al. Type of fatty acids in maternal diets during pregnancy and/or lactation and metabolic consequences of the offspring. J Nutr Biochem. 2015; 26, 99–111.
KennedyA, MartinezK, SchmidtS, et al. Antiobesity mechanisms of action of conjugated linoleic acid. J Nutr Biochem. 2010; 21, 171–179.
BaumanD, BaumgardL, CorlB, et al. Biosynthesis of conjugated linoleic acid in ruminants. J Anim Sci. 2000; 77, 1–15.
ViladomiuM, HontecillasR, Bassaganya-RieraJ. Modulation of inflammation and immunity by dietary conjugated linoleic acid. Eur J Pharmacol. 2015; 785, 87–95.
DhimanTR, NamS, UreAL. Factors affecting conjugated linoleic acid content in milk and meat. Crit Rev Food Sci Nutr. 2005; 45, 463–482.
BanniS. Conjugated linoleic acid metabolism. Curr Opin Lipidol. 2002; 13, 261–266.
WestDB, DelanyJP, CametPM, et al. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol. 1998; 275, R667–R672.
HouseknechtKL, HeuvelJPV, Moya-CamarenaSY, et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun. 1998; 244, 678–682.
KritchevskyD, TepperSA, WrightS, et al. Influence of graded levels of conjugated linoleic acid (CLA) on experimental atherosclerosis in rabbits. Nutr Res. 2002; 22, 1275–1279.
de RoosB, RucklidgeG, ReidM, et al. Divergent mechanisms of cis9, trans11-and trans10, cis12-conjugated linoleic acid affecting insulin resistance and inflammation in apolipoprotein E knockout mice: a proteomics approach. FASEB J. 2005; 19, 1746–1748.
JaudszusA, KrokowskiM, MockelP, et al. Cis-9, trans-11-conjugated linoleic acid inhibits allergic sensitization and airway inflammation via a PPARgamma-related mechanism in mice. J Nutr. 2008; 138, 1336–1342.
MoloneyF, ToomeyS, NooneE, et al. Antidiabetic effects of cis-9, trans-11-conjugated linoleic acid may be mediated via anti-inflammatory effects in white adipose tissue. Diabetes. 2007; 56, 574–582.
Bassaganya-RieraJ, ReynoldsK, Martino-CattS, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology. 2004; 127, 777–791.
BeluryMA, Moya-CamarenaSY, LuM, et al. Conjugated linoleic acid is an activator and ligand for peroxisome proliferator-activated receptor-gamma (PPAR gamma). Nutr Res. 2002; 22, 817–824.
ChengW, LiiC, ChenH, et al. Contribution of conjugated linoleic acid to the suppression of inflammatory responses through the regulation of the NF-κB pathway. J Agric Food Chem. 2004; 52, 71–78.
ReynoldsCM, LoscherCE, MoloneyAP, et al. Cis-9, trans-11-conjugated linoleic acid but not its precursor trans-vaccenic acid attenuate inflammatory markers in the human colonic epithelial cell line Caco-2. Br J Nutr. 2008; 100, 13–17.
ReynoldsCM, DraperE, KeoghB, et al. A conjugated linoleic acid-enriched beef diet attenuates lipopolysaccharide-induced inflammation in mice in part through PPARgamma-mediated suppression of toll-like receptor 4. J Nutr. 2009; 139, 2351–2357.
ParkY, StorksonJM, AlbrightKJ, et al. Evidence that the trans-10, cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids. 1999; 34, 235–241.
SegoviaSA, VickersMH, ZhangXD, et al. Maternal supplementation with conjugated linoleic acid in the setting of diet-induced obesity normalises the inflammatory phenotype in mothers and reverses metabolic dysfunction and impaired insulin sensitivity in offspring. J Nutr Biochem. 2015; 26, 1448–1457.